Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

Background and Objective: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to 4 weeks of age. To support pediatric dosing of dolutegravir in children, we used a population pharmacokinetic model with dolutegravir data from the P1093 and ODYSSEY clinical trials. The relationship between dolutegravir exposure and selected safety endpoints was also evaluated. // Methods: A population pharmacokinetic model was developed with data from P1093 and ODYSSEY to characterize the pharmacokinetics and associated variability and to evaluate the impact of pharmacokinetic covariates. The final population pharmacokinetic model simulated exposures across weight bands, doses, and formulations that were compared with established adult reference data. Exploratory exposure–safety analyses evaluated the relationship between dolutegravir pharmacokinetic parameters and selected clinical laboratory parameters and adverse events. // Results: A total of N = 239 participants were included, baseline age ranged from 0.1 to 17.5 years, weight ranged from 3.9 to 91 kg, 50% were male, and 80% were black. The final population pharmacokinetic model was a one-compartment model with first-order absorption and elimination, enabling predictions of dolutegravir concentrations in the pediatric population across weight bands and doses/formulations. The predicted geometric mean trough concentration was comparable to the adult value following a 50-mg daily dose of dolutegravir for all weight bands at recommended doses. Body weight, age, and formulation were significant predictors of dolutegravir pharmacokinetics in pediatrics. Additionally, during an exploratory exposure–safety analysis, no correlation was found between dolutegravir exposure and selected safety endpoints or adverse events. // Conclusions: The dolutegravir dosing in children ≥ 4 weeks of age on an age/weight-band basis provides comparable exposures to those historically observed in adults. Observed pharmacokinetic variability was higher in this pediatric population and no additional safety concerns were observed. These results support the weight-banded dosing of dolutegravir in pediatric participants currently recommended by the World Health Organization

Pharmacokinetics and dynamics of atovaquone and proguanil (Malarone R)

Malarone® is a fixed dose combination of atovaquone and proguanil and is mainly used for prophylaxis against P. falciparum malaria as an alternative to Lariamo® or chloroquine+proguanil. Knowledge of pharmacokinetics (PK) and pharmacodynamics (PD) is required to describe, quantify, and predict drug effects in humans in order to achieve desired therapeutic activity with minimum side effects. PK and PD of Malarone® were therefore studied with the aim to contribute to a better understanding of interactions among atovaquone, proguanil and cycloguanil and/or with other coadministered drugs. Our data suggest that PK of proguanil and cycloguanil are altered after multiple doses of Malarone® and PK of atovaquone are altered after concomitant administration with ketoconazole or rifampicin. Atovaquone appears to alter the PK of proguanil and cycloguanil at steady state after multiple daily doses of Malarone® in healthy individuals. In vitro enzyme kinetics experiments suggest inhibition of catalytic activity of CYP3A4 by atovaquone. Ketoconazole, an inhibitor of CYP3A4 and membrane transport proteins, significantly increased the oral bioavailability of atovaquone, upon coadministration with Malarone®. In contrast, rifampicin, an inducer of CYP3A4 and membrane transport proteins, increased clearance of atovaquone. The alteration in PK may indirectly suggest involvement of CYP3A4 in metabolism and/or transport proteins in active uptake and/or efflux of atovaquone. In vitro, at clinically relevant drug concentrations and combination ratios, atovaquone and proguanil exhibit synergistic PD interactions against P. falciparum parasites in vitro. Furthermore, low concentrations of proguanil, approximately equivalent to 0.2 times its EC90 value, are sufficient to enhance the effect of atovaquone. In contrast to this, interactions between atovaquone and cycloguanil were mainly antagonistic. Hence, the reduced cycloguanil concentrations after multiple doses of Malarone® will not be detrimental to its efficacy. Some P. falciparum parasites, exposed to various concentrations of atovaquone with or without proguanil, seem to adopt a 'dormant state' and survive for up to 24 days in cultures. These parasites show no genetic alterations thereby suggesting some other mechanism of escape from the drug effects. We report Malarone® treatment failures in two patients with P. falciparum malaria. Molecular analysis of parasitic DNA revealed mutations in cytochrome b gene (cytb) in one case but wild type alleles in the other. Also, the presence of mutant alleles in a third patient, who was cured, suggests that genetic mutations in cyth may be correlated but they are neither necessary nor sufficient condition to produce Malarone® resistance in vivo. In conclusion, high efficacy of Malarone® relies on synergistic interaction between atovaquone and proguanil and thus does not depend upon metabolism of proguanil to cycloguanil. Atovaquone seems to be a substrate for one or more membrane transport proteins. Thus, travelers on Malarone® prophylaxis, who may be taking other medications, may be predisposed to increased risk of drug-drug interactions. The presence of 'dormant state' parasites during exposure to atovaquone/proguanil suggests that factors other than cytb alterations may be involved as mechanisms of resistance to Malarone®

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.

BACKGROUND AND OBJECTIVE: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to 4 weeks of age. To support pediatric dosing of dolutegravir in children, we used a population pharmacokinetic model with dolutegravir data from the P1093 and ODYSSEY clinical trials. The relationship between dolutegravir exposure and selected safety endpoints was also evaluated. METHODS: A population pharmacokinetic model was developed with data from P1093 and ODYSSEY to characterize the pharmacokinetics and associated variability and to evaluate the impact of pharmacokinetic covariates. The final population pharmacokinetic model simulated exposures across weight bands, doses, and formulations that were compared with established adult reference data. Exploratory exposure-safety analyses evaluated the relationship between dolutegravir pharmacokinetic parameters and selected clinical laboratory parameters and adverse events. RESULTS: A total of N = 239 participants were included, baseline age ranged from 0.1 to 17.5 years, weight ranged from 3.9 to 91 kg, 50% were male, and 80% were black. The final population pharmacokinetic model was a one-compartment model with first-order absorption and elimination, enabling predictions of dolutegravir concentrations in the pediatric population across weight bands and doses/formulations. The predicted geometric mean trough concentration was comparable to the adult value following a 50-mg daily dose of dolutegravir for all weight bands at recommended doses. Body weight, age, and formulation were significant predictors of dolutegravir pharmacokinetics in pediatrics. Additionally, during an exploratory exposure-safety analysis, no correlation was found between dolutegravir exposure and selected safety endpoints or adverse events. CONCLUSIONS: The dolutegravir dosing in children ≥ 4 weeks of age on an age/weight-band basis provides comparable exposures to those historically observed in adults. Observed pharmacokinetic variability was higher in this pediatric population and no additional safety concerns were observed. These results support the weight-banded dosing of dolutegravir in pediatric participants currently recommended by the World Health Organization